News
EQS-News: BB BIOTECH AG: Molekulare Eingreiftruppen für das Immunsystem
EQS-Adhoc: BB Biotech AG veröffentlicht Zwischenbericht
EQS-News: BB BIOTECH AG: Biotech Industrie mit weiteren Innovationen als Antwort auf US Arzneimittelpreisregulierung
Lonza Appoints Daniel Palmacci as President of the Cell & Gene Division
DGAP-News: BB BIOTECH AG: Moderna war erst der Anfang
Lonza erzielt im ersten Halbjahr 2022 ein solides Ergebnis mit einem Umsatzwachstum von 16.8% (kWk) und einer Kern-EBITDA-Marge von 33.1%
Lonza Delivers Solid Performance in H1 2022 with 16.8% CER Sales Growth and 33.1% CORE EBITDA Margin
DGAP-Adhoc: BB Biotech AG veröffentlicht Zwischenbericht
DGAP-News: BB BIOTECH AG: Erste Anzeichen für vermehrte M&A-Aktivität aufgrund attraktiver Bewertungen
Maria Soler Nunez appointed as Head, Group Operations
DGAP-News: BB BIOTECH AG: Disruptive Technologien verändern einen ganzen Sektor
DGAP-Adhoc: BB Biotech AG veröffentlicht Zwischenbericht
DGAP-News: BB BIOTECH AG: Etablierte Kernbeteiligungen ermöglichen einen erhöhten Investitionsgrad
Vifor Pharma supports Iron Deficiency Day 2021: Call to action for early iron deficiency diagnosis
Already for the seventh consecutive year of Iron Deficiency Day, Vifor Pharma is supporting a growing international alliance including the Heart Failure Policy Network, European Kidney Health
Vifor Pharma to spearhead development of vascular calcification field, through acquisition of Sanifit Therapeutics and Inositec AG
Regulatory News:
AD HOC ANNOUNCEMENT PURSUANT TO ART. 53 LR
Vifor Pharma has announced the acquisition of Sanifit Therapeutics, a Spanish clinical-stage cardio-renal biopharmaceutical company
VFMCRP receives positive CHMP opinion for Tavneos® for the treatment of ANCA-associated vasculitis
Regulatory News:
AD HOC ANNOUNCEMENT PURSUANT TO ART. 53 LR
Vifor Fresenius Medical Care Renal Pharma (VFMCRP) today announced that the European Medicines Agency’s (EMA) CHMP has recommended
Vifor Pharma and Angion report topline results from phase-III registration trial of ANG-3777 in kidney transplant patients at risk for delayed graft function
Regulatory News:
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211026006150/en/
AD HOC ANNOUNCEMENT PURSUANT TO ART. 53 LR
Vifor
Vifor Pharma announces changes to its Executive Committee
Regulatory News:
AD HOC ANNOUNCEMENT PURSUANT TO ART. 53 LR
Vifor Pharma Group today announced changes to its Executive Committee as current members Lee Heeson, President International, and
VFMCRP announces approval for TAVNEOS® (avacopan) for the treatment of ANCA-associated vasculitis in Japan
Vifor Fresenius Medical Care Renal Pharma (VFMCRP) today announced that Japan’s Ministry of Health and Labor Welfare (MHLW) has granted its partner, Kissei Pharmaceutical Co., Ltd., marketing
GeNeuro and Northwestern University Enter Into a Research Collaboration on HERV-W ENV in Long-haul COVID
GeNeuro (Paris:GNRO) (Euronext Paris: CH0308403085 - GNRO), a biopharmaceutical company developing new treatments for neurodegenerative and autoimmune diseases, such as multiple sclerosis
Vifor Pharma and Travere Therapeutics announce licensing agreement for the commercialization of sparsentan in Europe, Australia and New Zealand
Regulatory News:
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210915005966/en/
AD HOC ANNOUNCEMENT PURSUANT TO ART. 53 LR
Vifor
Vifor Pharma’s Ferinject® granted new recommendations in updated 2021 ESC heart failure guidelines
Regulatory News:
Vifor Pharma is pleased to announce that the European Society of Cardiology (ESC) included new recommendations and proposals in the 2021 ESC guidelines for the diagnosis and
Vifor Pharma and Cara Therapeutics announce U.S. FDA approval of KORSUVA™ injection for the treatment of moderate-to-severe pruritus in hemodialysis patients
Regulatory News:
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210823005635/en/
Vifor Pharma and Cara Therapeutics (Nasdaq:CARA)
Vifor Pharma reports strong H1 2021 growth, on track to meet full year guidance1
Regulatory News:
Vifor Pharma Group reported profitable revenue growth in H1 supported by a strong recovery in Ferinject® / Injectafer® with sales up 22.8% at CER as a result of improved patient
Vifor Pharma erzielt im 1. Halbjahr 2021 starkes Wachstum und bestätigt Jahresprognose1
Regulatory News:
Die Vifor Pharma Gruppe erzielte im 1. Halbjahr 2021 ein profitables Umsatzwachstum dank einer starken Erholung von Ferinject®/Injectafer® mit einem Umsatzplus von 22.8% zu kWk
